| 1 | Personalized care approaches to hepatitis C therapy: recent advances and future directions | 4.0 | 4 | Citations (PDF) |
| 2 | Salvage Therapy with Rezafungin for Candida parapsilosis Spondylodiscitis: A Case Report from Expanded Access Program | 3.9 | 8 | Citations (PDF) |
| 3 | Role of Cefiderocol in Multidrug-Resistant Gram-Negative Central Nervous System Infections: Real Life Experience and State-of-the-Art | 4.3 | 9 | Citations (PDF) |
| 4 | Immune Profile in COVID-19: Unveiling TR3-56 Cells in SARS-CoV-2 Infection | 4.5 | 1 | Citations (PDF) |
| 5 | Treatment of Carbapenem-Resistant Acinetobacter baumannii in Real Life (T-ACI): A Prospective Single-Center Observational Study | 4.3 | 2 | Citations (PDF) |
| 6 | Urinary Tract Infections in Kidney Transplant Patients: An Open Challenge—Update on Epidemiology, Risk Factors and Management | 3.9 | 11 | Citations (PDF) |
| 7 | Invasive Fungal Infections in Hospitalized Patients with COVID-19: A Non-Intensive Care Single-Centre Experience during the First Pandemic Waves | 3.6 | 13 | Citations (PDF) |
| 8 | Remdesivir Alone or in Combination with Monoclonal Antibodies as an Early Treatment to Prevent Severe COVID-19 in Patients with Mild/Moderate Disease at High Risk of Progression: A Single Centre, Real-Life Study | 3.0 | 13 | Citations (PDF) |
| 9 | The Role of CRP POC Testing in the Fight against Antibiotic Overuse in European Primary Care: Recommendations from a European Expert Panel | 3.0 | 23 | Citations (PDF) |
| 10 | Diabetes and SARS-CoV-2 Infection: The Potential Role of Antidiabetic Therapy in the Evolution of COVID-19 | 3.9 | 1 | Citations (PDF) |
| 11 | CEFTO-CURE study: CEFTObiprole Clinical Use in Real-lifE – a multi-centre experience in Italy | 4.0 | 19 | Citations (PDF) |
| 12 | Stenotrophomonas maltophilia Infections: A Systematic Review and Meta-Analysis of Comparative Efficacy of Available Treatments, with Critical Assessment of Novel Therapeutic Options | 4.3 | 27 | Citations (PDF) |
| 13 | Obesity as a Risk Factor of Severe Outcome of COVID-19: A Pair-Matched 1:2 Case–Control Study | 2.6 | 24 | Citations (PDF) |
| 14 | Prevalence and Epidemiological and Clinical Features of Bacterial Infections in a Large Cohort of Patients Hospitalized for COVID-19 in Southern Italy: A Multicenter Study | 4.3 | 0 | Citations (PDF) |
| 15 | Prognostic Value of Creatinine Levels at Admission on Disease Progression and Mortality in Patients with COVID-19—An Observational Retrospective Study | 3.1 | 15 | Citations (PDF) |
| 16 | Risk Factors for Pneumocystis jirovecii Pneumonia in Non-HIV Patients Hospitalized for COVID-19: A Case-Control Study | 3.6 | 3 | Citations (PDF) |
| 17 | Oral Vancomycin Prophylaxis for Primary and Secondary Prevention of Clostridioides difficile Infection in Patients Treated with Systemic Antibiotic Therapy: A Systematic Review, Meta-Analysis and Trial Sequential Analysis | 4.3 | 30 | Citations (PDF) |
| 18 | A prospective study of direct‐acting antiviral effectiveness and relapse risk in HCV cryoglobulinemic vasculitis by the Italian PITER cohort | 10.6 | 29 | Citations (PDF) |
| 19 | Loss of Detection of sgN Precedes Viral Abridged Replication in COVID-19-Affected Patients—A Target for SARS-CoV-2 Propagation | 4.5 | 8 | Citations (PDF) |
| 20 | Management of hepatitis B virus prophylaxis in patients treated with disease-modifying therapies for multiple sclerosis: a multicentric Italian retrospective study | 3.5 | 22 | Citations (PDF) |
| 21 | Reliability of fr-AGILE tool to evaluate multidimensional frailty in hospital settings for older adults with COVID-19 | 2.9 | 4 | Citations (PDF) |
| 22 | Inducible Nitric Oxide Synthase (iNOS): Why a Different Production in COVID-19 Patients of the Two Waves? | 3.3 | 16 | Citations (PDF) |
| 23 | Serum galectin-3 and aldosterone: potential biomarkers of cardiac complications in patients with COVID-19 | 1.2 | 12 | Citations (PDF) |
| 24 | Sotrovimab in Solid Organ Transplant Patients With Early, Mild/Moderate SARS-CoV-2 Infection: A Single-center Experience | 1.2 | 19 | Citations (PDF) |
| 25 | Diabetes and COVID-19: The potential role of mTOR | 6.2 | 19 | Citations (PDF) |
| 26 | SARS-CoV-2 in Kidney Transplant Patients: A Real-Life Experience | 2.6 | 10 | Citations (PDF) |
| 27 | A Phase II Study on the Effect of Taurisolo® Administered via AEROsol in Hospitalized Patients with Mild to Moderate COVID-19 Pneumonia: The TAEROVID-19 Study | 4.8 | 9 | Citations (PDF) |
| 28 | Germline rare variants of lectin pathway genes predispose to asymptomatic SARS-CoV-2 infection in elderly individuals | 4.3 | 10 | Citations (PDF) |
| 29 | Impact of an anti-infective screening and monitoring protocol together with infectious disease consultation in preventing infective adverse events in patients treated with anti-CD20/CD52 agents for multiple sclerosis | 2.2 | 2 | Citations (PDF) |
| 30 | Prognostic Value of Transaminases and Bilirubin Levels at Admission to Hospital on Disease Progression and Mortality in Patients with COVID-19—An Observational Retrospective Study | 3.1 | 17 | Citations (PDF) |
| 31 | Lymphocyte Population Changes at Two Time Points during the Acute Period of COVID-19 Infection | 2.6 | 9 | Citations (PDF) |
| 32 | Serological Response and Clinical Protection of Anti-SARS-CoV-2 Vaccination and the Role of Immunosuppressive Drugs in a Cohort of Kidney Transplant Patients | 3.3 | 4 | Citations (PDF) |
| 33 | Epidemiology, Mechanisms of Resistance and Treatment Algorithm for Infections Due to Carbapenem-Resistant Gram-Negative Bacteria: An Expert Panel Opinion | 4.3 | 30 | Citations (PDF) |
| 34 | Calprotectin Levels and Neutrophil Count Are Prognostic Markers of Mortality in COVID-19 Patients | 3.0 | 9 | Citations (PDF) |
| 35 | Nirmatrelvir/Ritonavir and Molnupiravir in the Treatment of Mild/Moderate COVID-19: Results of a Real-Life Study | 3.0 | 54 | Citations (PDF) |
| 36 | Trends in Caesarean Section Rate According to Robson Group Classification among Pregnant Women with SARS-CoV-2 Infection: A Single-Center Large Cohort Study in Italy | 2.6 | 7 | Citations (PDF) |
| 37 | Update on the Management of Surgical Site Infections | 4.3 | 30 | Citations (PDF) |
| 38 | A Simple Non-Invasive Score Based on Baseline Parameters Can Predict Outcome in Patients with COVID-19 | 3.0 | 1 | Citations (PDF) |
| 39 | Evaluation of Drug Interactions in Patients Treated with DAAs for Hepatitis C Therapy with Comorbidities and Cardiovascular Issues—A Delphi Consensus Project | 2.6 | 3 | Citations (PDF) |
| 40 | Clinical Characterization of the Three Waves of COVID-19 Occurring in Southern Italy: Results of a Multicenter Cohort Study | 3.1 | 9 | Citations (PDF) |
| 41 | Risk factors for candidaemia in hospitalized patients with liver cirrhosis: a multicentre case–control–control study | 5.5 | 39 | Citations (PDF) |
| 42 | Heparin in COVID-19 Patients Is Associated with Reduced In-Hospital Mortality: The Multicenter Italian CORIST Study | 4.2 | 95 | Citations (PDF) |
| 43 | Serum KL-6 Could Represent a Reliable Indicator of Unfavourable Outcome in Patients with COVID-19 Pneumonia | 3.1 | 29 | Citations (PDF) |
| 44 | Nasopharyngeal Microbiome Signature in COVID-19 Positive Patients: Can We Definitively Get a Role to Fusobacterium periodonticum? | 4.3 | 73 | Citations (PDF) |
| 45 | Dysregulation of lipid metabolism and pathological inflammation in patients with COVID-19 | 3.5 | 140 | Citations (PDF) |
| 46 | Prospective Study on Incidence, Risk Factors and Outcome of Recurrent Clostridioides difficile Infections | 2.6 | 14 | Citations (PDF) |
| 47 | <i>Pneumocystis jirovecii</i> pneumonia in an immunocompetent patient recovered from COVID-19 | 1.8 | 24 | Citations (PDF) |
| 48 | Changing epidemiology of patients treated with direct acting antivirals for HCV and persistently high SVR12 in an endemic area for HCV infection in Italy: real-life ‘LIver Network Activity’ (LINA) cohort update results | 2.5 | 2 | Citations (PDF) |
| 49 | Clinical Features of Patients with Home Isolation Sars-Cov-2 Infection: A Multicenter Retrospective Study in Southern Italy | 2.8 | 4 | Citations (PDF) |
| 50 | Common variants at 21q22.3 locus influence MX1 and TMPRSS2 gene expression and susceptibility to severe COVID-19 | 3.6 | 72 | Citations (PDF) |
| 51 | Risk of invasive fungal infections among patients treated with disease modifying treatments for multiple sclerosis: a comprehensive review | 2.7 | 15 | Citations (PDF) |
| 52 | Incidence of cerebral venous thrombosis and COVID-19 vaccination: possible causal effect or just chance? | 4.1 | 12 | Citations (PDF) |
| 53 | Chest CT in COVID-19 patients: Structured vs conventional reporting | 2.9 | 14 | Citations (PDF) |
| 54 | B-Type Natriuretic Peptides and High-Sensitive Troponin I as COVID-19 Survival Factors: Which One Is the Best Performer? | 2.6 | 11 | Citations (PDF) |
| 55 | The TNFRSF13C H159Y Variant Is Associated with Severe COVID-19: A Retrospective Study of 500 Patients from Southern Italy | 2.6 | 17 | Citations (PDF) |
| 56 | Prognostic Role of Neutrophil to Lymphocyte Ratio in COVID-19 Patients: Still Valid in Patients That Had Started Therapy? | 2.9 | 23 | Citations (PDF) |
| 57 | Lopinavir/Ritonavir and Darunavir/Cobicistat in Hospitalized COVID-19 Patients: Findings From the Multicenter Italian CORIST Study | 2.6 | 25 | Citations (PDF) |
| 58 | Disentangling the Association of Hydroxychloroquine Treatment with Mortality in Covid-19 Hospitalized Patients through Hierarchical Clustering | 1.8 | 4 | Citations (PDF) |
| 59 | Gastrointestinal tract diseases as a risk factor for SARSCoV2 rectal shedding? An Italian report on 10 COVID-19 patients | 3.1 | 5 | Citations (PDF) |
| 60 | Case Report: Discovery a Novel SARS-CoV-2 Variant in a Six-Months Long-Term Swab Positive Female Suffering From Non-Hodgkin Lymphoma | 2.7 | 1 | Citations (PDF) |
| 61 | Daptomycin versus Vancomycin for the Treatment of Methicillin-Resistant Staphylococcus aureus Bloodstream Infection with or without Endocarditis: A Systematic Review and Meta-Analysis | 4.3 | 44 | Citations (PDF) |
| 62 | Further Findings Concerning Endothelial Damage in COVID-19 Patients | 4.4 | 10 | Citations (PDF) |
| 63 | The Serum Metabolome of Moderate and Severe COVID-19 Patients Reflects Possible Liver Alterations Involving Carbon and Nitrogen Metabolism | 4.5 | 74 | Citations (PDF) |
| 64 | Soluble Urokinase Receptor as a Promising Marker for Early Prediction of Outcome in COVID-19 Hospitalized Patients | 2.6 | 17 | Citations (PDF) |
| 65 | Pneumocystis jirovecii Pneumonia in Non-HIV Patients Recovering from COVID-19: A Single-Center Experience | 3.1 | 31 | Citations (PDF) |
| 66 | Post-mortem diagnosis of invasive pulmonary aspergillosis after alemtuzumab treatment for multiple sclerosis | 4.1 | 23 | Citations (PDF) |
| 67 | Ceftolozane/tazobactam for difficult-to-treat Pseudomonas aeruginosa infections: A systematic review of its efficacy and safety for off-label indications | 4.0 | 43 | Citations (PDF) |
| 68 | Efficacy and safety of a fixed dose combination tablet of asunaprevir + beclabuvir + daclatasvir for the treatment of Hepatitis C | 2.2 | 11 | Citations (PDF) |
| 69 | Seronegative occult HBV reactivation complicated with fulminant acute liver failure after rituximab for chronic inflammatory demyelinating polyneuropathy | 1.8 | 4 | Citations (PDF) |
| 70 | Current trends in the real-life use of dalbavancin: report of a study panel | 4.0 | 29 | Citations (PDF) |
| 71 | Common cardiovascular risk factors and in-hospital mortality in 3,894 patients with COVID-19: survival analysis and machine learning-based findings from the multicentre Italian CORIST Study | 3.4 | 149 | Citations (PDF) |
| 72 | Prohibitin 2 is Involved in Parkin-Mediated Mitophagy in Urothelial Cells of Cattle Infected with Bovine Papillomavirus | 3.1 | 12 | Citations (PDF) |
| 73 | Risk Factors for Candidemia After Open Heart Surgery: Results From a Multicenter Case–Control Study | 0.8 | 13 | Citations (PDF) |
| 74 | Prevalence of SARS-CoV-2 Antibodies in Multiple Sclerosis: The Hidden Part of the Iceberg | 2.6 | 20 | Citations (PDF) |
| 75 | Immunocytometric analysis of COVID patients: A contribution to personalized therapy? | 4.7 | 38 | Citations (PDF) |
| 76 | SARS-CoV-2 and liver damage: a possible pathogenetic link | 1.4 | 7 | Citations (PDF) |
| 77 | Direct acting antivirals treatment for hepatitis C virus infection does not increase the incidence of de novo hepatocellular carcinoma occurrence | 1.3 | 7 | Citations (PDF) |
| 78 | Efficacy and safety of ceftolozane/tazobactam as therapeutic option for complicated skin and soft tissue infections by MDR/XDR Pseudomonas aeruginosa in patients with impaired renal function: a case series from a single-center experience | 3.2 | 4 | Citations (PDF) |
| 79 | Changes in the relative prevalence of candidaemia due to non‐<i>albicans Candida</i> species in adult in‐patients: A systematic review, meta‐analysis and meta‐regression | 3.3 | 59 | Citations (PDF) |
| 80 | Advanced liver disease outcomes after hepatitis C eradication by human immunodeficiency virus infection in PITER cohort | 4.5 | 12 | Citations (PDF) |
| 81 | Novel strategies for the management of bacterial and fungal infections in patients with liver cirrhosis: focus on new antimicrobials | 4.0 | 5 | Citations (PDF) |
| 82 | No Detection of SARS-CoV-2 RNA on Urethral Swab in Patients with Positive Nasopharyngeal Swab | 1.0 | 4 | Citations (PDF) |
| 83 | The role of curcumin in liver diseases | 1.2 | 25 | Citations (PDF) |
| 84 | Invasive pulmonary aspergillosis and pulmonary tuberculosis in a patient treated with infliximab for Crohn’s disease | 0.8 | 9 | Citations (PDF) |
| 85 | Real‐life glecaprevir/pibrentasvir in a large cohort of patients with hepatitis C virus infection: The MISTRAL study | 4.1 | 33 | Citations (PDF) |
| 86 | Patients with HCV Genotype-1 who have Failed a Direct-Acting Antiviral Regimen: Virological Characteristics and Efficacy of Retreatment | 2.1 | 5 | Citations (PDF) |
| 87 | Meet Our Editorial Board Member | 1.1 | 0 | Citations (PDF) |
| 88 | Interferon-free regimens improve kidney function in patients with chronic hepatitis C infection | 1.6 | 26 | Citations (PDF) |
| 89 | Incidence and Predictive Risk Factors of Infective Events in Patients With Multiple Sclerosis Treated With Agents Targeting CD20 and CD52 Surface Antigens | 0.8 | 29 | Citations (PDF) |
| 90 | Carbapenem-sparing strategy: carbapenemase, treatment, and stewardship | 3.5 | 57 | Citations (PDF) |
| 91 | Severe Vitamin D Deficiency Increases Mortality Among Patients With Liver Cirrhosis Regardless of the Presence of HCC | 1.3 | 20 | Citations (PDF) |
| 92 | Direct-acting antivirals improve endothelial function in patients with chronic hepatitis: a prospective cohort study | 3.2 | 27 | Citations (PDF) |
| 93 | Unsolved Issues in the Treatment of Spontaneous Peritonitis in Patients with Cirrhosis: Nosocomial Versus Community-acquired Infections and the Role of Fungi | 1.1 | 7 | Citations (PDF) |
| 94 | Real-World Efficacy and Safety of Pangenotypic Direct-Acting Antivirals Against Hepatitis C Virus Infection | 1.1 | 34 | Citations (PDF) |
| 95 | NS5B polymerase inhibitors in phase II clinical trials for HCV infection | 4.0 | 13 | Citations (PDF) |
| 96 | Virological patterns of HCV patients with failure to interferon‐free regimens | 3.8 | 15 | Citations (PDF) |
| 97 | Are third-generation cephalosporins still the empirical antibiotic treatment of community-acquired spontaneous bacterial peritonitis? A systematic review and meta-analysis | 1.4 | 37 | Citations (PDF) |
| 98 | Meet Our Editorial Board Member | 1.1 | 0 | Citations (PDF) |
| 99 | Prevalence of HSV1/2 Congenital Infection Assessed Through Genome Detection on Dried Blood Spot in Individuals with Autism Spectrum Disorders | 1.3 | 3 | Citations (PDF) |
| 100 | Current evidence on the management of hepatitis B in pregnancy | 2.3 | 6 | Citations (PDF) |
| 101 | Risk of opportunistic infections in patients treated with alemtuzumab for multiple sclerosis | 2.7 | 58 | Citations (PDF) |
| 102 | Liver fungal infections: an overview of the etiology and epidemiology in patients affected or not affected by oncohematologic malignancies | 2.8 | 28 | Citations (PDF) |
| 103 | Current and emerging pharmacotherapy for the treatment of bacterial peritonitis | 2.2 | 10 | Citations (PDF) |
| 104 | Treatment with direct-acting antivirals improves the clinical outcome in patients with HCV-related decompensated cirrhosis: results from an Italian real-life cohort (Liver Network Activity—LINA cohort) | 4.5 | 56 | Citations (PDF) |
| 105 | Interferon-Free Regimens in Hepatitis B Surface Antigen/Anti–Hepatitis C Virus Positive Patients: The Need to Control Hepatitis B Virus Replication to Avoid Hepatitis B Virus Reactivation | 6.2 | 18 | Citations (PDF) |
| 106 | ITPase Activity Modulates the Severity of Anaemia in HCV-Related Cirrhosis Treated with Ribavirin-Containing Interferon-Free Regimens | 2.1 | 12 | Citations (PDF) |
| 107 | No Evidence of Congenital Varicella Zoster Virus Infection Assessed Through Dried Blood Spot in Children With Autism Spectrum Disorders | 1.2 | 1 | Citations (PDF) |
| 108 | Infections worsen prognosis of patients with cirrhosis irrespective of the liver disease stage | 2.9 | 16 | Citations (PDF) |
| 109 | Management of multidrug-resistant <i>Pseudomonas aeruginosa</i> in the intensive care unit: state of the art | 4.0 | 54 | Citations (PDF) |
| 110 | Vitamin D deficiency is a risk factor for infections in patients affected by HCV-related liver cirrhosis | 2.2 | 32 | Citations (PDF) |
| 111 | Successful treatment of post-surgical osteomyelitis caused by XDR Pseudomonas aeruginosa with ceftolozane/tazobactam monotherapy | 3.2 | 16 | Citations (PDF) |
| 112 | Spontaneous peritonitis in critically ill cirrhotic patients: a diagnostic algorithm for clinicians and future perspectives | 2.1 | 20 | Citations (PDF) |
| 113 | Current concepts and future strategies in the antimicrobial therapy of emerging Gram-positive spontaneous bacterial peritonitis | 2.3 | 52 | Citations (PDF) |
| 114 | Direct acting antiviral agents and hepatocellular carcinoma development: don’t take it for granted | 1.9 | 4 | Citations (PDF) |
| 115 | Is Anticoagulation with Novel Oral Anticoagulants an Effective Treatment for Tuberculosis Patients not Achieving a Therapeutic Range with Vitamin K Antagonists? A Systematic Review | 0.7 | 7 | Citations (PDF) |
| 116 | Prevalence of Congenital Cytomegalovirus Infection Assessed Through Viral Genome Detection in Dried Blood Spots in Children with Autism Spectrum Disorders | 1.3 | 19 | Citations (PDF) |
| 117 | Diagnostic Accuracy of PIVKA-II, Alpha-Fetoprotein and a Combination of both in Diagnosis of Hepatocellular Carcinoma in Patients Affected by Chronic HCV Infection | 1.3 | 20 | Citations (PDF) |
| 118 | The therapeutic potential of new investigational hepatitis C virus translation inhibitors | 4.0 | 14 | Citations (PDF) |
| 119 | CB2-63 polymorphism and immune-mediated diseases associated with HCV chronic infection | 2.4 | 10 | Citations (PDF) |
| 120 | Investigational direct-acting antivirals in hepatitis C treatment: the latest drugs in clinical development | 4.0 | 19 | Citations (PDF) |
| 121 | Lack of evidence that adherence to standard of care therapy improves survival in subjects with hepatocellular carcinoma in clinical practice | 3.8 | 3 | Citations (PDF) |
| 122 | Hepatocellular carcinoma in chronic HBV-HCV co-infection is correlated to fibrosis and disease duration | 1.6 | 55 | Citations (PDF) |
| 123 | Fecal microbiota transplantation for<i>Clostridium difficile</i>infection: back to the future | 3.1 | 18 | Citations (PDF) |
| 124 | Asunaprevir, a protease inhibitor for the treatment of hepatitis C infection | 2.1 | 35 | Citations (PDF) |
| 125 | Efficacy and Safety of Sofosbuvir in the Treatment of Chronic Hepatitis C: The Dawn of a New Era | 1.1 | 27 | Citations (PDF) |
| 126 | Vertical transmission of hepatitis B virus: challenges and solutions | 2.4 | 77 | Citations (PDF) |
| 127 | Anti-HBc positivity was associated with histological cirrhosis in patients with chronic hepatitis C | 1.6 | 33 | Citations (PDF) |
| 128 | Investigational nucleoside and nucleotide polymerase inhibitors and their use in treating hepatitis C virus | 4.0 | 29 | Citations (PDF) |
| 129 | Prevention of mother-to-child transmission of hepatitis B virus and hepatitis C virus | 4.0 | 32 | Citations (PDF) |
| 130 | ABT-450: A Novel Protease Inhibitor for the Treatment of Hepatitis C Virus Infection | 2.6 | 41 | Citations (PDF) |
| 131 | Dasabuvir: A Non-Nucleoside Inhibitor of NS5B for the Treatment of Hepatitis C Virus Infection | 1.1 | 47 | Citations (PDF) |
| 132 | Antibiotic prophylaxis and risk of infections in thyroid surgery: results from a national study (UEC—Italian Endocrine Surgery Units Association) | 1.8 | 27 | Citations (PDF) |
| 133 | Movement disorders as presenting symptoms of AIDS | 0.4 | 2 | Citations (PDF) |
| 134 | Erectile dysfunction in patients with chronic viral hepatitis: a systematic review of the literature | 2.2 | 25 | Citations (PDF) |
| 135 | Etiopathogenesis of autism spectrum disorders: Fitting the pieces of the puzzle together | 0.7 | 39 | Citations (PDF) |
| 136 | Resolution of autoimmune thrombocytopenia associated with raltegravir use in an HIV-positive patient | 2.5 | 11 | Citations (PDF) |
| 137 | A Simple Noninvasive Score Based on Routine Parameters can Predict Liver Cirrhosis in Patients With Chronic Hepatitis C | 0.5 | 25 | Citations (PDF) |
| 138 | Role of interleukin 28-B in the spontaneous and treatment-related clearance of HCV infection in patients with chronic HBV/HCV dual infection | 2.7 | 38 | Citations (PDF) |
| 139 | Sustained virological response: A milestone in the treatment of chronic hepatitis C | 4.8 | 64 | Citations (PDF) |
| 140 | Hepatitis B in pregnancy | 4.8 | 191 | Citations (PDF) |
| 141 | Is the drug-induced hypersensitivity syndrome (DIHS) due to human herpesvirus 6 infection or to allergy-mediated viral reactivation? Report of a case and literature review | 2.8 | 66 | Citations (PDF) |
| 142 | Development and progression of gastroesophageal varices in patients with chronic hepatitis C | 4.0 | 0 | Citations (PDF) |
| 143 | Surrogate endpoints and non-inferiority trials in chronic viral hepatitis | 3.6 | 23 | Citations (PDF) |
| 144 | The efficacy and safety of telaprevir – a new protease inhibitor against hepatitis C virus | 4.0 | 48 | Citations (PDF) |
| 145 | Iron depletion before HCV antiviral therapy: A pilot, randomized, controlled trial | 2.4 | 24 | Citations (PDF) |
| 146 | Homocysteine levels and sustained virological response to pegylated‐interferon α2b plus ribavirin therapy for chronic hepatitis C: a prospective study | 4.1 | 30 | Citations (PDF) |
| 147 | A Simple Noninvasive Score Predicts Gastroesophageal Varices in Patients With Chronic Viral Hepatitis | 2.4 | 32 | Citations (PDF) |
| 148 | Multiple Sclerosis and Hepatitis C Virus Infection Are Associated with Single Nucleotide Polymorphisms in Interferon Pathway Genes | 1.7 | 45 | Citations (PDF) |
| 149 | A rare case of brainstem encephalitis by Listeria monocytogenes with isolated mesencephalic localization. Case report and review | 1.7 | 32 | Citations (PDF) |
| 150 | A case of pegylated interferon alpha-related diabetic ketoacidosis: can this complication be avoided? | 2.4 | 27 | Citations (PDF) |
| 151 | Case Report: Hemolytic Anemia During Pegylated IFN-α2b Plus Ribavirin Treatment for Chronic Hepatitis C: Ribavirin Is Not Always the Culprit | 1.7 | 23 | Citations (PDF) |
| 152 | HIV and Hepatitis C Virus: Facts and
Controversies | 3.2 | 10 | Citations (PDF) |
| 153 | Case Report: Pernicious Anemia During IFN-α Treatment for Chronic Hepatitis C | 1.7 | 22 | Citations (PDF) |
| 154 | Myasthenia Gravis During Low-Dose IFN-α Therapy for Chronic Hepatitis C | 1.7 | 39 | Citations (PDF) |
| 155 | Multivariate Discriminant Function Based on Six Biochemical Markers in Blood Can Predict the Cirrhotic Evolution of Chronic Hepatitis | 1.1 | 54 | Citations (PDF) |
| 156 | A Case of Paracoccidioidomycosis: Experience with Long-Term Therapy | 3.2 | 15 | Citations (PDF) |
| 157 | Italian doctors call for protecting healthcare workers and boosting community surveillance during covid-19 outbreak | 0.2 | 79 | Citations (PDF) |
